Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Current Molecular Pharmacology|May 11, 2011
Crosstalk Signalling Role in Modulation of Drugs Side EffectsSusanna P Garamszegi, Nandor GaramszegiJournal of Cellular and Molecular Medicine|August 2, 2011
Matrix metalloproteinase-1 contribution to sarcoma cell invasionNandor Garamszegi, Susanna P Garamszegi, Sean P ScullyMolecular and Cellular Biology|November 13, 2003
Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3Mark C Wilkes, Stephen J Murphy, Nandor Garamszegi, et al.Molecular Cancer Research : MCR|March 12, 2009
Extracellular matrix-induced gene expression in human breast cancer cellsNandor Garamszegi, Susanna P Garamszegi, Lina A Shehadeh, et al.Experimental Biology and Medicine (Maywood, N.J.)|March 30, 2007
Molecular mechanism of tenascin-C action on matrix metalloproteinase-1 invasive potentialKarine A Galoian, Nandor Garamszegi, Susanna P Garamszegi, et al.Cancer Research|April 19, 2007
Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responsesKaori Suzuki, Mark C Wilkes, Nandor Garamszegi, et al.Molecular and Cellular Biology|June 8, 2002
Internalization-dependent and -independent requirements for transforming growth factor beta receptor signaling via the Smad pathwaySumedha G Penheiter, Hugh Mitchell, Nandor Garamszegi, et al.Journal of Cellular Physiology|October 23, 2004
siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell lineXiaoling Jiang, Charyl M Dutton, Wen-Ning Qi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Absence of a correlation between the presence of a single nucleotide polymorphism in the matrix metalloproteinase 1 promoter and outcome in patients of chondrosarcomaYi-Chin Fong, Charyl M Dutton, Stephen S Cha, et al.Neuropharmacology|August 26, 2015
Noribogaine is a G-protein biased κ-opioid receptor agonistEmeline L Maillet, Nicolas Milon, Mari D Heghinian, et al.Pageof 2